PTD-DBM
Aliases: Protein Transduction Domain-Dvl Binding Motif
Last verified: 2026-09-24
The short version
PTD-DBM is known in the gray hair-growth story for one detail: in mouse models it worked topically in combination with valproic acid, and valproate alone has proven follicle effects. What share of the effect belongs to the peptide — nobody knows. In addition, the Wnt pathway is a double-edged sword: the same signal that drives follicular regeneration is the one wrongly activated in colorectal cancers. The cosmetics industry long ago chose safer Wnt modulators; gray PTD-DBM remains a laboratory reagent with an interesting bibliography and an improper application.
Identity & type
- Molecular type
- hybrid peptide
- Origin
- Designed: PTD (transduction domain) + DBM motif (Dvl binding); synthetic.
Mechanism of action
A hybrid peptide: a protein-transduction domain (cell entry) fused to a Dvl-binding motif that blocks the CXXC5–Dishevelled interaction; the result is released Wnt/beta-catenin signaling — the central pathway for the follicular cycle and osteogenesis.
not confirmed in humans
Dosing & routes
Official / clinical context
No official context exists.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Occasionally in experimental 'hair stack' protocols (topical, with microneedling), without published measurements; reports are inseparable from other routine components.
Unverified self-reports. Not medical advice. Not endorsement.
Protocol — official vs community
Official / label
No approved protocol exists — preclinical agent. PTD-DBM has only mouse hair- and bone-regeneration data (topical/injectable µg–mg doses); no human regimen exists.
Duration: —
The mechanism itself is the caution: chronic Wnt/beta-catenin activation is tumor-associated, so even a perfected formulation would carry a fundamental question.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
None.
Preclinical evidence
One tidy line of mouse studies from one group; reproduced at least once independently for the follicular model, but without larger scale.
Known risks
- Theoretical: non-selective Wnt pathway activationtheoretical
- Complete uncertainty of topical-form bioavailability in humanstheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Everything in humans — from skin penetration to effect
Frequently asked questions
References
- Lee SH et al. — PTD-DBM and valproic acid in hair regrowth (mouse models, 2015–2017)